Markets:

Overview

News

Currencies

International

Treasuries

BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

77.64 +1.15 (+1.50%)

Streaming Delayed Price Updated: 9:39 AM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BridgeBio Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET

Today 7:30 EST

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

December 22, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? ↗

December 22, 2025

Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?

Via The Motley Fool

Topics Regulatory Compliance

Earnings Scheduled For October 29, 2025 ↗

October 29, 2025

Via Benzinga

Earnings Outlook For BridgeBio Pharma ↗

October 28, 2025

Via Benzinga

How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint ↗

December 02, 2025

Shares of BridgeBio Pharma are nearing a record high as the small biotech company takes on drug behemoths Pfizer and Alnylam.

Via Investor's Business Daily

BridgeBio (BBIO) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

BridgeBio (BBIO) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

BridgeBio to Participate in December Investor Conferences

November 25, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

November 19, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 14, 2025

Via Benzinga

Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds

November 10, 2025

New York, NY – November 10, 2025 – The S&P 500 Healthcare sector presented a mixed picture today, with the broader index showing a modest uptick while significant segments, particularly health insurers...

Via MarketMinute

Topics Artificial Intelligence Economy Government

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations

November 08, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally

November 07, 2025

The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

BridgeBio to Participate in November Investor Conferences

November 04, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025

November 03, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings. ↗

October 30, 2025

The company easily beat third-quarter expectations and issued guidance that widely topped forecasts.

Via Investor's Business Daily

BridgeBio Pharma (NASDAQ:BBIO) Q3 2025 Revenue Beat Overshadowed by Widened Loss ↗

October 29, 2025

BridgeBio Pharma's Q3 2025 earnings show a major revenue beat driven by Attruby sales, but a widened quarterly loss led to a negative market reaction.

Via Chartmill

BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates

October 29, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio's Investigation Drug Outperforms Standard Therapy In Rare Calcium Disorder ↗

October 29, 2025

BridgeBio's Encaleret met its Phase 3 endpoint in ADH1, with 76% achieving calcium targets, supporting plans for FDA and EMA submissions in 2026.

Via Benzinga

BridgeBio Shares Second Positive Late-Stage Study Result In A Week – Calcium Disorder Drug Trial Yields Positive Results ↗

October 29, 2025

76% of the 67 participants administered Encaleret in the trial achieved both serum and urine calcium within the respective target ranges after 24 weeks of treatment.

Via Stocktwits

BridgeBio Pharma Lines Up Another 'Domino' As It Nears A Record High ↗

October 29, 2025

A second positive "domino" fell for BridgeBio on Wednesday after the company reported promising results in a genetic disease.

Via Investor's Business Daily

BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1

October 29, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

October 28, 2025

Via Benzinga

BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th

October 28, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Janus Henderson, Avidity Biosciences, BridgeBio Pharma And Other Big Stocks Moving Higher On Monday ↗

October 27, 2025

Via Benzinga

BBIO Stock Soars After Experimental Drug Shows Improvement In Inherited Muscle Disorder In Late-stage Trial ↗

October 27, 2025

BridgeBio now intends to file a new drug application for the therapy's approval in the first half of 2026.

Via Stocktwits

BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study

October 27, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week

October 24, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

October 03, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio's Acoramidis Cuts Risk Within Weeks In Rare Heart Condition ↗

September 29, 2025

BridgeBio Pharma, Inc. (NASDAQ: BBIO) on Sunday presented data from the ATTRibute-CM study.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.